MA14.01 Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer

Abstract

The population of EGFR exon 20 insertion (ex20ins) mutations includes a diverse array of insertion variants and represents 5%-10% of EGFR mutations in non–small cell lung cancer (NSCLC). Specific targeted therapies are not available for patients with EGFR ex20ins+ NSCLC, regardless of insertion variant status; however, mobocertinib and amivantamab are currently in development. Identifying patients with EGFR ex20ins is challenging due to the limited coverage of polymerase chain reaction (PCR) assays and relatively recent use of next-generation sequencing (NGS).